HOME
Hepatitis C
Hepatitis B
HIV and AIDS
HIV-HCV Coinfection
HIV-HBV Coinfection
 HIVandHepatitis.com
 Google Custom Search

CDC Finds Failure to Follow Proper Infection-control Procedures Put More than 60,000 People at Risk for Hepatitis B and C over the Past Decade

Hepatitis B virus (HBV) and hepatitis C virus (HCV) are efficiently transmitted through contact with blood and other body fluids and tissues, which potentially puts healthcare providers and patients at risk of infection during medical procedures.

Such transmission can be prevented by using proper infection-control practices, but all too often these are not employed, according to a review article by Nicola Thompson and colleagues in the January 6, 2009 Annals of Internal Medicine.

According to the article, in the past decade 33 outbreaks in U.S. non-hospital healthcare settings have resulted in 450 people acquiring HBV and/or HCV infection. In all these cases, transmission was presumably from patient to patient, caused by "failure of healthcare personnel to adhere to fundamental principles of infection control and aseptic technique."

"Difficult to detect and investigate, these recognized outbreaks indicate a wider and growing problem as health care is increasingly provided in outpatient settings in which infection control training and oversight may be inadequate," the authors wrote. "A comprehensive approach involving better viral hepatitis surveillance and case investigation, health care provider education and training, professional oversight, licensing, and public awareness is needed to ensure that patients are always afforded basic levels of protection against viral hepatitis transmission."

Below is a media announcement from the U.S. Centers for Disease Control and Prevention (CDC) describing the review findings.

CDC Study Says Failures to Follow Infection Practices Have Placed 60,000 Patients at Risk for Hepatitis B and C


In the last decade, more than 60,000 patients in the United States were asked to get tested for hepatitis B virus (HBV) and hepatitis C virus (HCV) because healthcare personnel in settings outside hospitals failed to follow basic infection control practices, according to a new study by the CDC.

This first full review of all the CDC investigations over the past 10 years of healthcare-associated viral hepatitis outbreaks appears in the Jan. 6, 2009 issue of the journal Annals of Internal Medicine.

"This report is a wake-up call," said Dr. John Ward, director of CDC's Division of Viral Hepatitis. "Thousands of patients are needlessly exposed to viral hepatitis and other preventable diseases in the very places where they should feel protected. No patient should go to their doctor for healthcare only to leave with a life-threatening disease."

In the United States, transmission of HBV and HCV while receiving healthcare has been considered uncommon. However, a review of CDC outbreak information revealed a total of 33 identified outbreaks outside of hospitals in 15 states, during the past decade: 12 in outpatient clinics, 6 in hemodialysis centers and 15 in long-term care facilities, resulting in 450 people acquiring HBV or HCV infection.

Patients were exposed to these potentially deadly diseases because healthcare personnel failed to follow basic infection control procedures and aseptic technique in injection safety. Reuse of syringes and blood-contamination of medications, equipment and devices were identified as common factors in these outbreaks.

"More and more patients in the United States receive their healthcare in outpatient settings," said Dr. Denise Cardo, director of CDC's Division of Healthcare Quality Promotion. "To protect patients, infection control training, professional oversight, licensing, innovative engineering controls and public awareness are needed in these healthcare settings."

CDC officials say the report shows the need for ongoing professional education for healthcare providers, as well as consistent state oversight in detecting and preventing the transmission of bloodborne pathogens in healthcare settings.

CDC assists local health departments by providing routine surveillance, outbreak investigation support, field personnel and lab expertise. CDC also works with key partners to ensure adherence to proper infection control practices.

CDC and its partners are working to address this important patient safety problem through a number of efforts, including:

Improving viral hepatitis surveillance, case investigation and outbreak response, such as support for health departments to thoroughly investigate all individuals identified to have HBV or HCV infection;

Strengthening the capacity of state and local viral hepatitis prevention programs;

Augmenting the CDC's National Healthcare Safety Network, the national surveillance system for tracking healthcare-associated infections, to collect outpatient setting information;

Partnering with the Hepatitis Outbreaks' National Organization for Reform (HONOReform), a patient advocacy foundation, to create patient and provider education materials;

Continued improvement of injection safety practices through educational outreach efforts with professional nursing and anesthesiology organizations;

Working with partners in the dialysis, diabetes and long-term care communities to promote safe care practices;

Working with regulators and professional societies to strengthen licensure and accreditation processes with emphasis on safe injection practices;

Exploring ways to improve curricula in nursing and medical schools related to safe healthcare practices.

For more information on preventing viral hepatitis in healthcare settings, visit www.cdc.gov.

1/30/09

Reference
N Thompson, JF Perz, AC Moorman, and SD Holmberg. Nonhospital Health Care-Associated Hepatitis B and C Virus Transmission: United States, 1998-2008. Annals of Internal Medicine 150(1): 33-39. January 6, 2009. (Abstract).

Other source
U.S. Department of Health and Human Services. Failures to Follow Infection Practices Have Placed More than 60,000 Patients at Risk for Hepatitis B and C. Press release. January 6, 2009.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


FDA-approved Therapies for Chronic HBV Infection
Baraclude  (entecavir)
Epivir-HBV  (lamivudine; 3TC)
Hepsera
  (adefovir dipivoxil)
Intron A
  (interferon alfa-2b)
Pegasys  (peginterferon alfa-2a)
Tenofovir   (viread)
Tyzeka   (telbivudine)
Experimental Treatment
HBV Articles by Topic